Frost & Sullivan choose Signalife -- from all others in heart monitoring - - through careful analysis that included interviews with major market participants and extensive secondary research. In accordance with Frost & Sullivan's strict policy of independence, the Company was not contacted prior to receiving notification that it was the recipient of the award.
Dr. Lowell T. Harmison -- Signalife's President and Chief Executive Officer -- commented: "I would like to personally thank Dr. Budimir Drakulic -- who I believe to be one of the most brilliant micro-electronics experts in the world -- as well as his team. It is not promotional to say that Signalife is now "over the top" in terms of giving this industry the means to change its core technology to obtain more accurate ECG's for better heart monitoring. As a result, it should alter the way heart disease is monitored, diagnosed and treated in general. Indeed, "over the top" are not my words -- they are Frost & Sullivan's. I personally look forward to unveiling a series of corporate events that will guide the profession to these solutions. Stay tuned."
Signalife will make the full Frost & Sullivan analyst report -- as well as other events surrounding the receipt of this prestigious award -- available to the public in the upcoming two weeks.
Signalife, Inc. is a life sciences company focused on the monitoring,
detection and prevention of disease through continuous biomedical signal
monitoring. Signalife uses its patented signal technology to design and
develop medical devices, therapies and/or technologies that simplify and
reduce the costs of cardiovascular
|SOURCE Signalife, Inc.|
Copyright©2008 PR Newswire.
All rights reserved